IL286729A - Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma - Google Patents

Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Info

Publication number
IL286729A
IL286729A IL286729A IL28672921A IL286729A IL 286729 A IL286729 A IL 286729A IL 286729 A IL286729 A IL 286729A IL 28672921 A IL28672921 A IL 28672921A IL 286729 A IL286729 A IL 286729A
Authority
IL
Israel
Prior art keywords
treatment
tyrosine kinase
kinase inhibitors
urinary tract
tract carcinoma
Prior art date
Application number
IL286729A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL286729A publication Critical patent/IL286729A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
IL286729A 2019-03-29 2021-09-26 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma IL286729A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166428 2019-03-29
EP19188971 2019-07-30
PCT/US2020/025166 WO2020205493A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
IL286729A true IL286729A (en) 2021-10-31

Family

ID=70296138

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286729A IL286729A (en) 2019-03-29 2021-09-26 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Country Status (15)

Country Link
US (1) US12691112B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946341A1 (cg-RX-API-DMAC7.html)
JP (2) JP7747521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210145211A (cg-RX-API-DMAC7.html)
CN (1) CN113645974A (cg-RX-API-DMAC7.html)
AU (1) AU2020253827B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019446A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130460A1 (cg-RX-API-DMAC7.html)
IL (1) IL286729A (cg-RX-API-DMAC7.html)
JO (1) JOP20210266A1 (cg-RX-API-DMAC7.html)
MA (1) MA55522A (cg-RX-API-DMAC7.html)
MX (1) MX2021011926A (cg-RX-API-DMAC7.html)
PH (1) PH12021552342A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109902SA (cg-RX-API-DMAC7.html)
WO (1) WO2020205493A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12277100B2 (en) * 2019-09-12 2025-04-15 Life Spectacular, Inc. Maintaining user privacy of personal, medical, and health care related information in recommendation systems
WO2022243467A1 (en) * 2021-05-19 2022-11-24 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
CN110785184A (zh) * 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法,组合物和试剂盒
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
MA47408B1 (fr) 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer
KR20210064274A (ko) 2018-09-21 2021-06-02 얀센 파마슈티카 엔.브이. 담관암종의 치료
BR112021015686A2 (pt) 2019-02-12 2021-10-26 Janssen Pharmaceutica N.V. Tratamento de câncer
US20220175768A1 (en) 2019-03-29 2022-06-09 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Also Published As

Publication number Publication date
US12691112B2 (en) 2026-07-28
CN113645974A (zh) 2021-11-12
JP2025156297A (ja) 2025-10-14
MX2021011926A (es) 2021-11-03
AU2020253827B2 (en) 2026-01-08
JP7747521B2 (ja) 2025-10-01
EP3946341A1 (en) 2022-02-09
PH12021552342A1 (en) 2022-08-22
KR20210145211A (ko) 2021-12-01
AU2020253827A1 (en) 2021-09-30
WO2020205493A1 (en) 2020-10-08
US20220054484A1 (en) 2022-02-24
MA55522A (fr) 2022-02-09
SG11202109902SA (en) 2021-10-28
CA3130460A1 (en) 2020-10-08
JOP20210266A1 (ar) 2023-01-30
JP2022527189A (ja) 2022-05-31
BR112021019446A2 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
LT3986897T (lt) Egfr inhibitorius, skirtas vėžiui gydyti
IL286727A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
IL284199A (en) Csf1r inhibitors for use in treating cancer
MA51616A (fr) Inhibiteurs d'adn-pk
MA45406A (fr) Inhibiteurs d'ezh2 pour traiter le cancer
EP3307728A4 (en) COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
IL290363A (en) Ripretinib for treating gastrointestinal stromal tumors
EP3962908A4 (en) HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
EP3399968A4 (en) SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANES OF EGFR-TYROSINE KINASE
PL3472153T3 (pl) Pirymidyn-2-yloamino-1h-pirazole jako inhibitory lrrk2 do zastosowania w leczeniu zaburzeń neurodegeneracyjnych
EA201591907A1 (ru) Ингибитор киназ
IL270693A (en) Glucuronide prodrugs of janus kinase inhibitors
EP3804707A4 (en) KINASE INHIBITOR
EP3927700A4 (en) KINAS INHIBITORS
EP3765008A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE
IL287745A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
EP3630080A4 (en) USE OF EZH2 INHIBITORS TO TREAT CANCER
EP3370725A4 (en) PEDIATRIC DOSAGE FOR THE TREATMENT OF CANCER WITH AN EZH2 INHIBITOR
IL286983A (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
DK3956322T3 (da) Jak1-selektiv kinaseinhibitor
IL288408A (en) Methods of treating urinary system cancers
IL282041A (en) Egfr inhibitors for treating keratodermas
PL3952858T3 (pl) Sposób leczenia guzów
IL290798A (en) Prodrugs of the tyrosine kinase inhibitor for treating cancer
EP3966204A4 (en) SUBSTITUTED 1-AMINO-1H-IMIDAZOLE-5-CARBOXAMIDE USED AS BRUTON'S TYROSINE KINASE INHIBITORS